Single centre experience on the use of low dose subcutaneous cytarabine in treatment of patients with high-risk myelodysplastic syndrome and acute myeloid leukaemia

被引：0
|
作者：
Schneider, T. [1 ]
Narayanan, S. [1 ]
机构：
[1] Univ Hosp Southampton NHS Fdn Trust, Dept Haematol, Southampton, Hants, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 157卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
161
引用
收藏
页码：63 / 63
页数：1
相关论文
共 50 条
  • [1] SINGLE CENTRE SURVIVAL OUTCOMES IN THE TREATMENT OF INTERMEDIATE AND HIGH-RISK MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKAEMIA WITH 5-AZACITIDINE
    Stringer, R.
    Rider, D. T.
    Newman, D. J.
    Grace, D. R.
    HAEMATOLOGICA, 2015, 100 : 725 - 726
  • [2] High-risk cytogenetic abnormalities in acute myeloid leukaemia - single centre experience
    Kamran, S.
    Mir, A.
    Ahmad, K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 192 - 193
  • [3] Antifungal prophylaxis in acute myeloid leukemia and high-risk myelodysplastic patients: a single centre experience
    Bergantim, R. B.
    Carvalhais, I.
    Trigo, F.
    Guimaraes, J. E.
    MYCOSES, 2009, 52 : 114 - 114
  • [4] Single Centre Experience in Treating Elderly Patients with Acute Myeloid Leukaemia or High Risk Myelodyplastic Syndrome with a Combination of Low Dose Cytarabine, Venetoclax and Fluconazole (VeLDAC-F)
    Child, Lauren
    Chan, Henry
    Henderson, Ross Alistair
    Elinder, Anna
    Merriman, Eileen
    Hanna, Merit
    Simpson, David
    BLOOD, 2018, 132
  • [5] Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
    Yamauchi, Takahiro
    Negoro, Eiju
    Arai, Hajime
    Ikegaya, Satoshi
    Takagi, Kazutaka
    Takemura, Haruyuki
    Inai, Kunihiro
    Yoshida, Akira
    Urasaki, Yoshimasa
    Iwasaki, Hiromichi
    Ueda, Takanori
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2635 - 2639
  • [6] Single centre experience of low dose cytarabine (LDAraC) treatment outcomes in myeloproliferative neoplasms (MPN), high risk myelodysplasia (MDS) and acute myeloid leukaemia (AML)
    Young, M. E.
    Arasaretnam, A. D.
    McLornan, D.
    De Lavallade, H.
    Pagliuca, T.
    Marsh, J.
    Kulasekararaj, A.
    Ireland, R.
    Potter, V.
    Raj, K.
    Mufti, G. J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 76 - 76
  • [7] Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome
    Márcio Tavares
    Sérgio Chacim
    José Mário Mariz
    Annals of Hematology, 2021, 100 : 837 - 839
  • [8] Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome
    Tavares, Marcio
    Chacim, Sergio
    Mariz, Jose Mario
    ANNALS OF HEMATOLOGY, 2021, 100 (03) : 837 - 839
  • [9] Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Cortes, Jorge E.
    Heidel, Florian H.
    Hellmann, Andrzej
    Fiedler, Walter
    Smith, B. Douglas
    Robak, Tadeusz
    Montesinos, Pau
    Pollyea, Daniel A.
    DesJardins, Pierre
    Ottmann, Oliver
    Ma, Weidong Wendy
    Shaik, M. Naveed
    Laird, A. Douglas
    Zeremski, Mirjana
    O'Connell, Ashleigh
    Chan, Geoffrey
    Heuser, Michael
    LEUKEMIA, 2019, 33 (02) : 379 - 389
  • [10] Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Jorge E. Cortes
    Florian H. Heidel
    Andrzej Hellmann
    Walter Fiedler
    B. Douglas Smith
    Tadeusz Robak
    Pau Montesinos
    Daniel A. Pollyea
    Pierre DesJardins
    Oliver Ottmann
    Weidong Wendy Ma
    M. Naveed Shaik
    A. Douglas Laird
    Mirjana Zeremski
    Ashleigh O’Connell
    Geoffrey Chan
    Michael Heuser
    Leukemia, 2019, 33 : 379 - 389
12345